Changes in trade and other receivables -2,042.7 -1,328.2 Change in provisions 0.0 453.0 Other changes in trade liabilities, contract liabilities and other liabilities 1,337.6 -870.7 Interest paid -212.0 -382.2 Interest received 0.1 0.2 Taxes paid -0.9 -4.4 Cash flow utilized by operating activities -6,884.9 -7,640.7 Purchase of property, plant and equipment and intangible assets -3,963.5 -2,340.9 Investments in financial assets 0.0 -35.0 Cash flow utilized by investing activities -3,963.5 -2,375.9 Proceeds from shareholders 0.0 22,425.0 Convertible bond repayments 0.0 -24.8 Proceeds of long-term borrowings 8,000.0 4,000.0 Repayments of shareholders' loans 0.0 -2,262.7 Proceeds from equity-settled options 306.0 0.0 Repayments of long-term borrowings -210.0 -1,891.1 Lease payments -78.7 -98.4 Equity transaction costs -11.7 -1,779.5 EIB loan transaction costs 0.0 -47.9 Cash flow generated from financing activities 8,005.6 20,320.7 Sum of cash flows -2,842.9 10,304.1 Effect of initial consolidation of Marino Immo GmbH 30.2 0.0 Total change in cash & cash equivalents -2,812.7 10,340.1 Cash and cash equivalents at beginning of the period 12,019.6 1,715.5 Cash and cash equivalents at the end of the period 9,206.9 12,019.6
About Marinomed Biotech AG Marinomed Biotech AG (Korneuburg, Austria) (VSE:MARI) is an Austrian science-based biotech company with globally marketed therapeutics listed on the Prime Market of the Vienna Stock Exchange. The company focuses on the development of innovative products based on two patent-protected technology platforms. The Marinosolv^(R) technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as eyes, nose, lung or gastrointestinal tract. The Carragelose^(R) platform comprises innovative patent-protected products targeting viral infections of the respiratory tract and can reduce the risk of an infection with SARS-CoV-2. Carragelose^(R) is used in nasal sprays, throat sprays and lozenges, which are sold via international partners in over 40 countries worldwide. Marinomed, Marinosolv^(R) and Carragelose^(R) are registered trademarks of Marinomed AG. These trademarks may be owned or licensed in select locations only. Further information is available at https://www.marinomed.com/en/ technologies-markets/markets.
For further inquiries contact:
Marinomed Biotech AG International Media and IR Contact
Pascal Schmidt, CFO MC Services AG
Hovengasse 25, 2100 Korneuburg, Austria Dr. Brigitte Keller, Julia Hofmann
T +43 2262 90300 T +49 89 210228 0
E-mail: ir@marinomed.com E-mail: marinomed@mc-services.eu
http://www.marinomed.comDisclaimer This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as "anticipate," "believe", "estimate", "expect", "intend", "plan", "project" and "target". Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. -----------------------------------------------------------------------------------------------------------------------
2021-04-14 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de -----------------------------------------------------------------------------------------------------------------------
1184356 2021-04-14
(END) Dow Jones Newswires
April 14, 2021 01:45 ET (05:45 GMT)
